GEP20166435B - Treatments for gastrointestinal disorders - Google Patents

Treatments for gastrointestinal disorders

Info

Publication number
GEP20166435B
GEP20166435B GEAP201012738A GEAP2010012738A GEP20166435B GE P20166435 B GEP20166435 B GE P20166435B GE AP201012738 A GEAP201012738 A GE AP201012738A GE AP2010012738 A GEAP2010012738 A GE AP2010012738A GE P20166435 B GEP20166435 B GE P20166435B
Authority
GE
Georgia
Prior art keywords
gastrointestinal disorders
treatments
pharma
peptides
treatment
Prior art date
Application number
GEAP201012738A
Other languages
English (en)
Inventor
Mark G Currie
Angelika Fretzen
Marco Kessler
Daniel P Zimmer
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43503086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20166435(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of GEP20166435B publication Critical patent/GEP20166435B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
GEAP201012738A 2009-11-09 2010-11-09 Treatments for gastrointestinal disorders GEP20166435B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25926409P 2009-11-09 2009-11-09

Publications (1)

Publication Number Publication Date
GEP20166435B true GEP20166435B (en) 2016-02-25

Family

ID=43503086

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201012738A GEP20166435B (en) 2009-11-09 2010-11-09 Treatments for gastrointestinal disorders

Country Status (26)

Country Link
US (3) US20140179607A9 (cg-RX-API-DMAC7.html)
EP (1) EP2499154B1 (cg-RX-API-DMAC7.html)
JP (1) JP5913115B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120115495A (cg-RX-API-DMAC7.html)
CN (1) CN102812038B (cg-RX-API-DMAC7.html)
AR (1) AR078950A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010314866B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012011730A2 (cg-RX-API-DMAC7.html)
CA (1) CA2779482A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012001186A1 (cg-RX-API-DMAC7.html)
CO (1) CO6551683A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120303A (cg-RX-API-DMAC7.html)
EA (1) EA022817B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011962A (cg-RX-API-DMAC7.html)
ES (1) ES2620153T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20166435B (cg-RX-API-DMAC7.html)
IL (1) IL219596A0 (cg-RX-API-DMAC7.html)
MX (2) MX350046B (cg-RX-API-DMAC7.html)
NZ (1) NZ599751A (cg-RX-API-DMAC7.html)
PH (1) PH12012500916B1 (cg-RX-API-DMAC7.html)
SG (1) SG10201407403UA (cg-RX-API-DMAC7.html)
TW (1) TWI482626B (cg-RX-API-DMAC7.html)
UA (1) UA114274C2 (cg-RX-API-DMAC7.html)
UY (2) UY33018A (cg-RX-API-DMAC7.html)
WO (1) WO2011057272A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201203342B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2012510518A (ja) * 2008-12-02 2012-05-10 アイロンウッド ファーマシューティカルズ，インコーポレーテッド 体液貯留障害を処置するための方法および組成物
GEP20166435B (en) * 2009-11-09 2016-02-25 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
CN102822194B (zh) * 2009-12-07 2016-10-26 硬木药品公司 用于胃肠病症的治疗
CA2835624A1 (en) * 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9303066B2 (en) 2011-05-11 2016-04-05 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US20160213739A1 (en) * 2011-05-11 2016-07-28 Ironwood Pharmaceuticals, Inc Treatments for disorders using guanylate cyclase c agonists
WO2012170804A1 (en) * 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012170766A1 (en) * 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
MX347354B (es) * 2011-08-17 2017-04-24 Ironwood Pharmaceuticals Inc Tratamientos para trastornos gastrointestinales.
JP2016521249A (ja) * 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド リナクロチド組成物
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
US20160235807A1 (en) * 2013-10-09 2016-08-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
WO2016015055A1 (en) * 2014-07-25 2016-01-28 Ironwood Pharmaceuticals, Inc. Colon cleansing compositions
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB290795A (en) 1927-04-08 1928-05-24 British Colour Printing Compan Improvements in or relating to advertising or display devices
US5962220A (en) 1993-10-26 1999-10-05 Thomas Jefferson University Compositions that specifically bind to colorectal cells and methods of using the same
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
DE69433564T2 (de) 1993-10-26 2004-12-23 Thomas Jefferson University Verbindungen, die kolorektale Krebszellen spezifisch binden, und Verfahren zu ihrer Verwendung
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
WO2001080871A2 (de) * 2000-04-22 2001-11-01 Ipf Pharmaceuticals Gmbh Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2
DK1594517T3 (da) 2003-01-28 2007-10-29 Microbia Inc Sammensætninger til behandlingen af gastrointestinale lidelser
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2619650A1 (en) 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2559319T3 (es) * 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
SG193801A1 (en) 2008-08-15 2013-10-30 Ironwood Pharmaceuticals Inc Linaclotide-containing formulations for oral administration
US20120039949A1 (en) 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
GEP20166435B (en) * 2009-11-09 2016-02-25 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
US8748575B2 (en) 2010-06-09 2014-06-10 Combimab, Inc. Therapeutic peptides

Also Published As

Publication number Publication date
CA2779482A1 (en) 2011-05-12
CO6551683A2 (es) 2012-10-31
AR078950A1 (es) 2011-12-14
TWI482626B (zh) 2015-05-01
IL219596A0 (en) 2012-06-28
SG10201407403UA (en) 2014-12-30
PH12012500916B1 (en) 2018-03-23
AU2010314866A1 (en) 2012-05-31
JP2013510182A (ja) 2013-03-21
KR20120115495A (ko) 2012-10-18
UY33017A (es) 2011-06-30
WO2011057272A1 (en) 2011-05-12
EA201290322A1 (ru) 2013-01-30
US20130085107A1 (en) 2013-04-04
MX350046B (es) 2017-08-24
EP2499154A1 (en) 2012-09-19
ES2620153T3 (es) 2017-06-27
US20110118184A1 (en) 2011-05-19
CN102812038B (zh) 2016-05-18
CL2012001186A1 (es) 2013-07-12
MX2012005368A (es) 2012-06-13
UA114274C2 (uk) 2017-05-25
CN102812038A (zh) 2012-12-05
US8946158B2 (en) 2015-02-03
EA022817B1 (ru) 2016-03-31
US20140024593A1 (en) 2014-01-23
BR112012011730A2 (pt) 2016-03-08
JP5913115B2 (ja) 2016-05-11
TW201116291A (en) 2011-05-16
NZ599751A (en) 2014-08-29
US8507447B2 (en) 2013-08-13
ECSP12011962A (es) 2012-07-31
UY33018A (es) 2011-01-31
ZA201203342B (en) 2013-01-30
CR20120303A (es) 2012-08-08
EP2499154B1 (en) 2016-12-21
PH12012500916A1 (en) 2018-01-29
AU2010314866B2 (en) 2014-10-30
US20140179607A9 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
GEP20166435B (en) Treatments for gastrointestinal disorders
IN2012DN02805A (cg-RX-API-DMAC7.html)
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
UA103915C2 (ru) Твердая лекарственная форма, которая содержит линаглиптин и ингибитор sglt2, и ее применение
GB201118656D0 (en) New compounds
PH12015501806A1 (en) Novel benzopyran kinase modulators
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
IN2012MN02591A (cg-RX-API-DMAC7.html)
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
PT2482812T (pt) Composições farmacêuticas compreendendo bi-1356 e metformina
PH12013502382B1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
MX2011002966A (es) Formas de dosificacion farmaceutica que comprenden poli (e-caprolactona).
IL217777A (en) A peptide for the preparation of pain medication
IN2012DN00624A (cg-RX-API-DMAC7.html)
IN2012DN02471A (cg-RX-API-DMAC7.html)
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
WO2011072069A3 (en) Gastric retentive pharmaceutical compositions for extended release of polypeptides
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
MY184647A (en) Arylated camphenes, processes for their preparation and uses thereof
EP2490721A4 (en) COMPOSITIONS, TREATMENT PROCEDURES AND DIAGNOSIS OF AUTOIMMUN-MEDIATED ILLNESSES AND METHOD FOR THE PREPARATION OF SUCH COMPOSITIONS
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity
IT1397446B1 (it) Compositions comprising amino acids for prevention and/or treatment of renal disorders.